If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection has been a recognized concern in medical literature for years, forming part of the established pharmacovigilance framework for biologic therapies. This page explains how clinicians evaluate and monitor PML risk in Tysabri patients.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. The label identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy. PML typically occurs only in immunocompromised individuals. The JC virus, which causes PML, is usually latent but can reactivate under certain conditions. Tysabri works by blocking alpha-4 integrin, which prevents immune cells from crossing the blood-brain barrier. This mechanism, while effective for reducing multiple sclerosis relapses, also impairs normal immune surveillance in the central nervous system, allowing JC virus to replicate unchecked. The clinical presentation of PML includes progressive neurological deficits such as weakness, cognitive decline, vision loss, and coordination problems. Diagnosis relies on MRI imaging and detection of JC virus DNA in cerebrospinal fluid. Adverse event reports from the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these are common in multiple sclerosis patients generally, PML represents a distinct and far more serious complication. The label instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
For patients in Ohio who have been harmed by Tysabri-associated PML, the statute of limitations is a key legal consideration. In Ohio, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule means the clock starts when the patient or their representative becomes aware of the link between Tysabri and the PML diagnosis. Given that PML can develop months to years after starting Tysabri, and symptoms may initially mimic multiple sclerosis relapses, the timing of discovery can be complex. Patients who received Tysabri for extended periods, especially beyond two years, are at higher risk and should be vigilant for any new neurological symptoms. The adequacy of warnings is another important factor. The boxed warning on Tysabri clearly states the PML risk and the need for monitoring. However, some patients may argue that the warnings were insufficient or that healthcare providers did not adequately communicate the risks. The TOUCH Prescribing Program, a restricted distribution program, is designed to ensure that patients are informed and monitored, but lapses in this process could potentially form the basis of a claim. For affected patients and their families, consulting with an attorney experienced in pharmaceutical litigation is advisable. The attorney can help determine the applicable statute of limitations based on the specific facts of the case, including the date of PML diagnosis and when the connection to Tysabri was recognized. Medical records documenting the timeline of Tysabri use, onset of symptoms, and PML diagnosis are essential evidence. In summary, Tysabri carries a known risk of PML, with identifiable risk factors including anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. Ohio patients who develop PML should be aware of the two-year statute of limitations from the date of discovery. Legal counsel can provide guidance on whether the warnings were adequate and whether a claim is timely.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule means the clock starts when the patient or their representative becomes aware of the link between Tysabri and the PML diagnosis.
The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.